Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

March 1, 2022

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 73 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and thanks for holding. We're glad to have you on this Bayer call for investors and analysts covering the complete 2021 year along with the fourth-quarter figures. During the recorded portion of today's session, everyone will be in listen-only mode. After the presentation, we'll open things up for questions and answers. Should anyone on the line need help from an operator, just hit the star key and then zero on your phone. At this point, I'll hand things over to Mr. Oliver Maier, who leads Investor Relations at Bayer AG. Over to you, sir.

Oliver Maier

executive
#2

Thank you very much, Nairobi. Good afternoon, and thanks for being with us today. I want to welcome everyone to our conference call covering the fourth quarter and the full year 2021. Joining me today are Werner Baumann, our CEO, and Wolfgang Nickl, our CFO. The divisions are represented by the management board members responsible for them. The layout is a bit different for the fiscal year. Werner will start today's call by covering the 2021 highlights and setting out the year that lies ahead. After that, Rodrigo, Stefan, and Heiko will each comment on how their businesses performed and give the divisional outlook for 2022. Wolfgang will close things out with an overview of group performance and the outlook before we open the floor for the Q&A session. As usual, I'd like to point you to the cautionary language contained in our safe harbor statement and in all the materials we have distributed today. With that, I'll turn it over to you, Werner.

Werner Baumann

executive
#3

Okay, thank you, Oliver, and good afternoon everyone. I'm glad to have you join this conference call. Before we turn to business performance, I want to begin with the issue that is undoubtedly foremost on everyone's mind. The Russian invasion of Ukraine has unsettled the geopolitical order, and we feel profound shock and worry over what the Ukrainian people are enduring. This war amounts to nothing less than a danger to our freedom and democracy, and at Bayer we denounce this Russian attack in the strongest possible terms. Although we hope coordinated political steps will soon help better the situation, we as a company are striving to act as a dependable partner and a responsible corporate citizen, staying true to our vision, Health for All, Hunger for None. Naturally, the safety of our employees is our highest priority now, and we are adopting every suitable measure to safeguard our 700 colleagues in the Ukraine. Simultaneously, we are making every effort to keep ensuring that our products reach the civilian population, among them essential medicines and agricultural products needed to protect food supplies. Naturally, we stand ready to expand our humanitarian assistance through financial contributions and donations of our medical products, as we demonstrated throughout the COVID pandemic.

Werner Baumann

executive
#4

Alright, there isn’t going to be a seamless handoff here, but let me pull back a bit and talk through a few important macro items that mattered to our business over the last year. We encountered especially supportive conditions in agriculture, with soft commodity prices running high and worldwide supply staying tight, which pushed glyphosate prices higher. In pharma, elective procedures picked up again once the COVID-19 restrictions in 2020 eased, and in consumer health we continued to see rising demand for preventive health products. On the negative side, we observed mounting inflationary pressure and greater instability in global supply chains across industries. Let me also give you a quick status update on the glyphosate litigation. In December, the U.S. Supreme Court asked the Solicitor General for its views in the Roundup Hardeman case. Regardless of what that brief concludes, two possible paths exist. Should the Supreme Court agree to review Hardeman after receiving the Solicitor General’s input and ultimately decide in our favor, that would in effect bring the glyphosate litigation to an end. If the Supreme Court declines to take the case for review or ultimately rules against us, we will launch the voluntary claims administration program within our five-point plan to help bring the litigation to closure. Financially speaking, we have already built this particular scenario into our 2021 provisions.

Werner Baumann

executive
#5

Let's now turn to how the business performed. It's a real pleasure to report that we beat the upgraded guidance we shared alongside our Q3 earnings release. Bayer began 2021 as a year of transition, yet we closed it with considerable momentum, giving us a solid foundation for additional growth and earnings expansion in 2022. On the whole, with a supportive market backdrop, our results came in well above what we had anticipated at the start of the year. We lifted the top line considerably, by 9%, with robust contributions from every division. Crop Science reinforced its position in the market, gaining share, especially in corn, and continuing to expand in fungicides. On top of that, we recorded significant price increases right across the portfolio, above all for products based on glyphosate, as global supply stayed tight. Pharmaceuticals posted yet another year of healthy growth for our key products, Eylea and Xarelto, even with the first effects of volume-based procurement in China for Xarelto. We also returned to the U.S. cardiology market and benefited from encouraging contributions from our launch products. Consumer Health achieved industry-leading growth across regions and categories, with an emphasis on executional excellence and innovation. That considerable volume growth, together with strong pricing and the contributions from our ongoing performance programs, helped us more than offset inflationary pressure and cost normalization following an exceptional 2020, while still allowing us to invest in launches and innovation.

Werner Baumann

executive
#6

Even so, our reported results in euro were constrained by substantial FX headwinds — about EUR 1 billion affecting the top line and roughly EUR 500 million on the bottom line. Next, innovation, which matters greatly for the growth we'll deliver going forward. We've advanced considerably on our innovation agenda and see a promising 2022 ahead. In Pharmaceuticals, key approvals have been secured and we're moving into the commercialization phase for new products, which leaves our late-stage pipeline substantially de-risked. With Nubeqa, Kerendia, and Verquvo — our new products — launch momentum remains strong and we intend additional rollouts during 2022. Along those lines, we very recently obtained approval to market Kerendia in the European Union. Only a week ago, for the prostate cancer drug Nubeqa, we lifted our peak sales expectation from more than EUR 1 billion to now more than EUR 3 billion. Considerable headway was also made on our early-stage pipeline through our cell and gene therapy platform, and our drug discovery capabilities were reinforced by acquiring Vividion Therapeutics. Regarding Xarelto, our number one product, the patent ruling came back positive, confirming our once daily administration patent in the EU. As a result, exclusivity for our most important pharma product now extends until 2026 in Europe, which complements the 2027 exclusivity extension already secured in the U.S.

Werner Baumann

executive
#7

Within Crop Science, we brought hundreds of next-generation corn and soybean seed products to market successfully and moved short stature corn forward. Considerable headway was also achieved on our digital platform — notably the successful debut of our carbon farming initiative, growth of our Orbia Digital Ag Marketplace in Brazil, and the signing of key collaboration agreements with Microsoft and other external partners. In Consumer Health, we recorded successful launches of Defense and Dry Skin and AleveX Topical Pain, along with regulatory clearance for the 2022 Rx-to-OTC switch of Astepro in the U.S., the first and only steroid-free nasal decongestant on the market. We likewise made considerable headway on our sustainability goals and the sustainable development of our businesses. At Crop Science, we are advancing carbon farming, an entirely novel business field that financially rewards farmers for adopting practices improving carbon sequestration into the soil. In Pharmaceuticals, we enable access to modern contraceptives by investing more than EUR 400 million into facilities in Costa Rica and Finland. At Consumer Health, we are investing 100 million euros to make our products more sustainable. Our intention is for packaging across all our consumer products to be recyclable or reusable by 2030. Looking ahead, our focus is on carrying the strong business momentum into 2022, translating into growth and earnings expansion.

Werner Baumann

executive
#8

We anticipate that this momentum will be heavily weighted toward the first half of the year. On the negative side, we expect inflationary cost pressures to continue and supply chains to stay stretched, which will make the supply situation very volatile across industries. In addition, our plans assumed a stable geopolitical environment in Eastern Europe, and that has changed dramatically in the meantime. We will monitor these risks closely and mitigate them as much as we can. Regarding innovation activities, we expect further important news flow across divisions in our Leaps entity in 2022, including the news we shared with you ten days ago on the ARASENS data for Nubeqa. I look forward to keeping you updated. Stefan will also outline the major pipeline in Pharma and the catalysts we are seeing for the coming year. I'd also like to take this opportunity to welcome Rodrigo Santos for his first earnings call. It's great to have Rodrigo on the team as a successor to Liam, and the business is off to a good start and a bright future under his leadership. Now over to you, Rodrigo.

Rodrigo Santos

executive
#9

Thank you, Werner, and I appreciate everyone being on the call with us today. I'm genuinely thrilled to start off by walking you through some outstanding results from the year just ended. Our pipeline made strong headway, as did our digital farm solutions, which line up well with what we're aiming for — reshaping agriculture toward a more sustainable future. Beyond that, we plainly showed what a market leader can deliver, picking up share in corn seeds and traits across key markets including Brazil and Argentina, and claiming the top brand spot in the U.S. That came on the back of new hybrid launches plus our next-generation, industry-first RNAi-based corn rootworm trait, which is part of the VT Pro4 offering in Brazil. On the soybean side, we rolled out Intacta 2 Xtend across more than 800,000 acres in its first year in Brazil, and we're looking for that to expand to 6 million acres next season. At the same time, in North America, we hit 16 million acres with XtendFlex during its first year of commercialization, which successfully safeguarded our standing as the number one soybean with control system in North America. I'm happy to report that pairing innovation with disciplined execution gave us record sales for Crop Science in 2021, with gains in every region and every business unit.

Rodrigo Santos

executive
#10

Higher prices for herbicides powered that 11.1% rise in sales, along with combined growth in fungicides, plus share gains in corn and both better pricing and volume improvement in soybean seeds and traits. Those results, together with the efficiency steps we keep taking, more than compensated for substantial cost inflation and for negative currency effects totaling EUR 387 million. That produced a 4% rise overall in EBITDA before special items, at a margin of 23.2%, or 24.3% at prior year currency rates, in line with the guidance we gave for the year. Looking ahead to 2022, we have two main objectives: to keep performing and transforming at the same time. With these results and this innovation behind us, along with high commodity prices, we see strong momentum as we enter 2022. Consequently, we are guiding to 7% sales growth and an EBITDA before special items margin of 25%-26%. Earnings growth overall should come from stronger prices, share gains and new efficiency steps, which we expect to more than offset ongoing inflationary cost pressures, especially in crop protection, where we, like the rest of the industry, are facing unprecedented supply chain challenges. Given those cost pressures and the value that our high-performance products create, we expect pricing to be the main contributor to our sales growth for the year.

Rodrigo Santos

executive
#11

We expect roughly half of the pricing growth to come from herbicides, with the other half coming from corn seeds and traits plus the remainder of our corn crop protection portfolio. The yearly refresh of our corn seed lineup, along with upgrades to next-generation technologies in insecticides and fungicides such as Fox Xpro, makes that growth possible through 6%-7% price increases globally. Although volume isn't projected to be as significant as pricing, we do expect share gains in corn and strong demand for fungicides to contribute to our overall growth. In our models, we expect herbicide prices to be higher in the first half of 2022 and lower in the second half, with possible improvement of the global supply of glyphosate. This trend influences our total outlook, with our total sales growth rate expected to be above 7% for the first half and below that level for the second half of the year. Similarly, our EBITDA before special items margin is expected to expand strongly in the first half and compress in the second half on the path to the 25%-26% for the full year. This year, however, is not expected to be without challenges. Our growth outlook in this plan is constrained by potential competitive dynamics and some regulatory uncertainty, plus some potential supply challenges across all our crop protection portfolio.

Rodrigo Santos

executive
#12

Farming has forever presented difficulties, and it always will. As the top player in this sector, our company is going to concentrate on capitalizing on the chances that innovation brings while striving to reduce the dangers. I'm eager to bring you up to date on how we're doing against this plan and on continuing work to reshape farming during the second half. With that said, I'll pass things to Stefan for an update on the pharma business.

Stefan Oelrich

executive
#13

Thanks, Rodrigo. I'm glad to do that, and good afternoon, everyone. After COVID-19 curtailed our patients' ability to obtain their medicines the year before, Bayer Pharma's top line recovered strongly in 2021. Sales rose 7%, a touch above the upgraded guidance we gave in August, on higher volumes, which climbed 9%. Our two flagship products accounted for roughly 60% of that increase. Eylea sales rose 19%, helped by a double-digit gain in every region and also supported by steadily rising adoption and increased shipments of the pre-filled syringes launched in 2020. Xarelto, our largest single sales contributor, also performed strongly in 2021, with 6% year-on-year growth. A healthy volume trend more than offset lower prices from volume-based procurement cuts in China, which began taking effect in September 2021 and were in place across all provinces by October. To wrap up my comments on last year's key top-line drivers, both Adalat and Adempas delivered roughly 20% growth in 2021. For Adempas, that included a one-time milestone payment of EUR 190 million received in the fourth quarter, reflecting strong market momentum that produced more than $1 billion of in-market sales in 2021.

Stefan Oelrich

executive
#14

So with that, we've now hit the last sales threshold that sets off milestone payments for this product. Turning to our late-stage assets, we successfully launched Kerendia in the United States last September. Even though we had limited ability to reach healthcare providers during the COVID-19 pandemic, we're excited to report that launch uptake is in line with other successful cardiovascular medicines introduced in the U.S. market, and we do expect this trend to continue. Just recently, the American Diabetes Association updated their guidelines with an A recommendation for the use of Kerendia for patients with chronic kidney disease who are at increased risk for cardiovascular events or chronic kidney disease progression. We also continue to make good progress with the rollout of Verquvo in the treatment of heart failure with reduced ejection fraction following last year's approvals in the U.S., Japan, and in the EU. The continued rollout of our new prostate cancer drug, Nubeqa, was particularly successful, generating sales of EUR 219 million in 2021. In the second year after market launch, it is already one of our top 15 products. This strong performance is the result of Nubeqa's unique clinical profile, which was impressively confirmed by a consistent set of strong efficacy and tolerability data from Nubeqa's second successful phase III ARASENS trial released two weeks ago.

Stefan Oelrich

executive
#15

We posted EBITDA before special items of EUR 5.8 billion — a 31.5% margin — so we also met our earnings guidance for 2021. As I emphasized a year ago, the 2020 margin was always going to be a hard act to follow, since it gained a great deal from the cost containment measures we put in place as COVID-19 was evolving. In 2021, heavier spending on innovation and on marketing for new products put pressure on profitability. For 2022, we're looking for divisional sales growth of 3%-4%. New launches are increasingly adding to the top line, in our view, and we expect Eylea to keep demonstrating its market-leading position with mid-single-digit % growth this year. All told, sales growth in the division should far outweigh the VBP pricing headwinds we face in China this year for Xarelto and Adalat. Keep in mind that 2021 Xarelto sales reflected only 4 months of adverse impact from China VBP, whereas this year it will be felt in full. Looking ahead, Xarelto should keep growing in Europe, our largest region, but elsewhere we're seeing more heterogeneous development, largely because of softer pricing and loss of exclusivity. To finish on China VBP, Adalat will probably show its first effects in the second half of this year.

Stefan Oelrich

executive
#16

Looking at late-stage pipeline news flow, we started the year on a strong note, with a second set of highly encouraging phase III clinical results from the ARASENS trial of Nubeqa, along with the EU approval for Kerendia. One of our key priorities for this year is to keep the launch momentum going for our late-stage pipeline assets and to get Nubeqa filed for the indication extension into metastatic hormone-sensitive prostate cancer. As for Eylea, we have two phase III studies underway right now with an 8-milligram formulation, and the goal is to potentially extend injection intervals and make things more convenient for patients while maintaining superior efficacy. Results from those studies are anticipated in the second half of this year. Beyond that, our Factor XI program is going to be phase III decision ready during this year, with a highly competitive profile that could ultimately end up leading in the class. Going after Factor XI in the anticoagulation pathway holds promise as a novel and disruptive way to decouple prevention from cardiovascular risks from bleeding risks. What's more, it could give options to patients for whom no treatments exist at all today. In the early phase of our pipeline, we might see news during this year that has the potential to be transformative in the fight against Parkinson's disease, an area of the utmost clinical need.

Stefan Oelrich

executive
#17

With DA01, our stem cell–based therapy candidate from BlueRock, we're working on a treatment that harnesses authentic dopaminergic neurons to reinnervate the affected areas of the human brain and reverse the degenerative process. Seven patients in total have been enrolled in this potentially groundbreaking procedure, and we expect interim data from the study during the second half of this year. The ongoing investments in technologies, along with the progress we're making in moving our pipeline from early to late stage through to launches and rollouts, reflect consistent execution of our strategy aimed at generating sustainable long-term growth. At the same time, our ambition is to keep returns attractive. With an EBITDA margin target before special items of around 32% for this year, we're committed to delivering on both fronts, backed by stringent cost management and a reallocation of resources. Now it's over to Heiko for an update on Consumer Health.

Heiko Schipper

executive
#18

Okay, thanks, Stefan, and good afternoon, everyone. I'm glad to walk you through how Consumer Health performed in 2021 and to give you our outlook for 2022 as well. To begin with 2021: we achieved strong, broad-based growth of 6.5% spanning every one of our regions and virtually all of our categories. We keep delivering at the top end of our industry, and that really shows the quality of our Consumer Health business, our brands, and our people. Put simply, these results demonstrate that we can execute our strategy and outperform in a competitive environment that keeps getting tougher. Nutritionals was once again the standout category. We've now posted strong double-digit growth in that category for 2 years running, with our power brands in particular — One A Day and Redoxon — doing very well. On top of that, our growth got a lift from successful launches behind brands such as Bepanthen and Aleve, which shows we can strengthen iconic brands through innovation that wins with customers and consumers. Cough and cold was a tale of two halves. The first half of the year came in negative because of a historically weak flu season. In the second half of 2021, we saw robust growth after many countries opened up.

Heiko Schipper

executive
#19

But that category ended 2021 a little under the prior year. Every one of our remaining categories posted growth in the mid to high single digits. Those contributions, broad-based as they were, put us once more ahead of the total market in 2021, which expanded roughly 4%. Turning to the bottom line. Disciplined operational execution of our strategy, sustained as before, delivered margin expansion again. During 2021, profitability rose 50 basis points, reaching 22.5%. Measured in absolute terms, earnings before special items came to EUR 1.2 billion. Disciplined spending along with pricing measures drove that margin expansion, offsetting inflationary cost increases while still letting us put money into marketing and innovation behind our brands. Now let's turn to the outlook and look ahead. Consumer Health is still fully on track to deliver its growth strategy successfully. For 2022, we anticipate 4%-5% growth, with innovation stepping up further. That growth will probably be front-loaded into the first half of the year, given an easier comp against 2021, particularly in cough and cold. Earnings before special items should land within the 22%-23% range. We are doing everything we can to offset rising input costs through efficiency measures and a focus on pricing.

Heiko Schipper

executive
#20

We also intend to boost spending on the brands supporting our launches, along with research and development. A key growth engine for 2022 and afterward is going to be the U.S. introduction of a new brand named Astepro. Approved as an over-the-counter product, it is the first and only steroid-free antihistamine nasal spray for allergies. For our business, this Rx-to-OTC switch marks a significant milestone, since it reinforces our leading allergy portfolio and provides a differentiated option for the 50 million Americans affected by allergies. To wrap up, we anticipate another exciting year for Bayer's Consumer Health business. Across the past 3 years, we have achieved growth at the forefront of our industry while also improving margins. With our leading brands, broad geographic footprint, and a proven track record of winning with consumers, we are well-placed to win in this market. With that, I will pass it to Wolfgang, who will walk you through our financials.

Wolfgang Nickl

executive
#21

Thanks, Heiko. Now I'll take you through the group's 2021 financials and pull together what my colleagues have said into the group outlook for fiscal year 2022. Net sales for the group reached EUR 44 billion, up 9% versus the prior year. That's EUR 1 billion ahead of the guidance we updated, and it includes a significant currency headwind of EUR 1.1 billion, which we had anticipated. The biggest impact comes from the U.S. dollar and the Brazilian real weakening against the euro, though the Japanese yen, Turkish lira, and Russian ruble played a part as well. Earnings before special items were EUR 11.2 billion, a decline of 3%, which gives a margin of 25.4%, in line with our latest guidance. A negative currency effect of about EUR 500 million weighed on group EBITDA, representing a 50 basis point margin decline versus the prior year. In our underlying operations, we were by and large able to offset inflationary pressure on input costs through adjusted pricing and efficiency gains, while at the same time increasing investments into innovation and product launches. Inflation particularly hit our costs for energy, active ingredients, freight, and labor. To give one example, global container freight cost for a forty-foot container rose from roughly $2,000 in 2020 to roughly $10,000 in 2021.

Wolfgang Nickl

executive
#22

Also, as we mentioned last year, we brought our cost profile back on short-term incentives when compared year over year, cycling over 50% payout in 2020. Core earnings per share rose 2% to EUR 6.51 and sit roughly 20 cents above the top end of our most recent guidance, currency impact included. Gains from Crop Science and Consumer Health offset weaker Pharma and Reconciliation results, along with a higher core tax rate. A stronger financial result added more than 30 cents, driven by lower interest rates on new financing and favorable currency effects, plus a positive remeasurement for our Leaps investments. The biggest gap between core earnings per share of EUR 6.51 and earnings per share of EUR 1.02 comes from higher provisions for the glyphosate litigation and costs tied to our restructuring programs, as laid out in the backup of the slide deck. Free cash flow reached EUR 1.4 billion. That marks a 5% rise versus the prior year, even with EUR 400 million more in net settlements and higher tax payments. This strong cash performance stemmed mainly from disciplined working capital management, especially in Crop Science. Against our updated guidance, net settlement payments came in lower than expected, at EUR 4.3 billion euro for the full year.

Wolfgang Nickl

executive
#23

Those elements also explain why net financial debt ended up EUR 2 billion above what our most recent guidance had indicated — better, I should say. Net financial debt rose year-over-year, moving from approximately EUR 30 billion to EUR 33 billion, driven chiefly by funding the division acquisition at EUR 1.2 billion, unfavorable foreign exchange impacts totaling EUR 900 million, and dividend distributions of EUR 2 billion, which together exceeded the free cash flow generated. I'd like to wrap up our presentation by turning to group guidance for 2022. First, let me note that this outlook is based on our current business and excludes any effect from the planned divestment of the professional portion of our Environmental Science business. I'd also ask you to keep in mind that an arbitration involving BASF — as is routinely disclosed in the annual report's risk section — is expected to wrap up around mid-2022, though it could conclude earlier. We have strong arguments defending our position and have therefore booked no provisions. Consistent with prior years, our guidance is framed at constant currencies — that is, using average actual 2021 exchange rates. The projected FX effect, assuming month-end December 2021 spot rates were applied, appears in the right-hand column and indicates a tailwind of approximately EUR 1 billion to net sales and 10 cents to Core EPS.

Wolfgang Nickl

executive
#24

We project sales for the Bayer Group at roughly EUR 46 billion, which represents growth of about 5%. Although we're making substantial investments in future growth—especially in Pharmaceuticals and Consumer Health—we anticipate margin expansion driven by robust top-line growth as well as additional benefits from our efficiency programs. We expect our EBITDA margin before special items to rise to roughly 26%, which would put absolute EBITDA before special items at around EUR 12 billion. According to the divisional projections, we foresee a strong weighting of both top-line and profitability toward the first half of the year, with an expected normalization during the second half. For core EPS, we are raising our guidance to approximately EUR 7 at constant currencies. As for the core tax rate, we are maintaining our guidance of approximately 23% for now. Should we see the proposed introduction of minimum taxes or attempts by governments under heavy pressure to refinance COVID-19 related expenditures to raise tax rates, that level would become increasingly difficult to achieve. We anticipate our reconciliation result at between -EUR 500 million and -EUR 600 million. The increase reflected versus the prior year is primarily due to the planned start of an upgrade to our system infrastructure. We remain strongly focused on cash generation and expect free cash flow to rise to a range of EUR 2 billion to EUR 2.5 billion.

Wolfgang Nickl

executive
#25

That figure covers the total net payouts we anticipate for litigation settlements, roughly EUR 2.5 billion, and it includes faith payouts tied to glyphosate settlements that were agreed before the Supreme Court asked the U.S. government for its opinion on the Hardeman case. Leaving settlements aside, our target for underlying free cash flow is about EUR 4.5 billion-EUR 5 billion. We forecast net financial debt in a range of EUR 33 billion-EUR 34 billion. Other major KPIs, please note, appear in the appendix of our investor presentation. For fiscal year 2021, we propose a dividend payment of EUR 2 per share, subject to approval by the AGM. At approximately 31%, the payout ratio stays inside the target corridor of 30%-40% of our core EPS. Oliver, with that I'll hand the call back to you so we can begin the Q&A.

Oliver Maier

executive
#26

Thanks a lot, Wolfgang. I appreciate everyone’s remarks and perspective. Just before we get started, I’d ask that you please limit yourselves to roughly two questions each, ideally, so we can get to as many questions as possible from as many people as we can. With that said, Nairobi, I believe you can go ahead and open the lines for questions.

Operator

operator
#27

Ladies and gentlemen, we're going to start the question-and-answer session at this point. Should you have a question, kindly press the star key and then the number one on your phone. To withdraw your request, press the star key followed by the number two. Should you be on speaker equipment today, please pick up the handset before you make your selections. Please hold for a moment while we take the first question. Our first question comes from Vincent Andrews at Morgan Stanley. You may proceed.

Vincent Andrews

analyst
#28

Thank you, and good morning to everyone. Rodrigo, I was hoping you might expand a bit on glyphosate pricing, and I'll combine my two questions into one. First, could you describe how you're approaching pricing for your product relative to where Chinese prices have moved, considering how parabolic the increase in Chinese prices has been? In the past, you generally aimed to set your price at $1 per gallon above the Chinese, but I believe if you actually did that now, your price would be considerably higher than what appears to be built into the guidance. So what is the strategy? For the second part, I suppose: you mentioned that in the back half of the year you expect prices to decline sequentially. Does that also imply that as we move into 2023, on a year-over-year basis, prices will likely be below 2022 but still likely above 2021? Or how should we be thinking about that in our models?

Rodrigo Santos

executive
#29

Thanks, Vincent. I'll spend a moment on glyphosate. When you look at what we're projecting for 2021, we land at roughly 15% growth in herbicides. Price is essentially what's driving that. As you'll recall, Hurricane Ida created a volume effect for us. Turning to 2022, we're seeing the same picture, correct? It's the reverse of what 2021 gave us — in 2021 we had a lower price during the first six months and a higher price over the second half, and this year we expect it the other way around. We're going to see a higher price across the first six months and a lower price over the rest of the year. At least that's how it looks today. Naturally, we'll keep working very closely on that to see whether we can capture any extra opportunities there. Vincent, I'd also like to reinforce the opportunity that we're guiding for 2022: half of our price increase comes from the herbicide side, and half comes from corn seeds and traits, fungicides, and insecticides. We're seizing that market opportunity, with discipline on execution, to drive that price increase for the year.

Rodrigo Santos

executive
#30

All in all, the first six months have been solid, and for the rest of the year we're projecting a lower figure, though we'll aim to seize whatever opportunities the market presents.

Operator

operator
#31

Mr. Andrews, are you done with your question?

Vincent Andrews

analyst
#32

Nope. I'll relay that. That's all I have, those 2.

Operator

operator
#33

Our next question comes from Peter Verdult's line. Please proceed.

Peter Verdult

analyst
#34

I appreciate it.

Operator

operator
#35

Peter Verdult.

Peter Verdult

analyst
#36

Sure, two things. Hi, Carsten Werner. When you look at consumer businesses trading at 5x sales, how do you think about making sure Bayer's consumer business receives the recognition it deserves? Since you believe you're performing well but your current share price isn't reflecting that. Then, for Rodrigo, to build on Vincent's question, regarding some of the headwinds you mentioned — regulatory, competitive, and supply issues. Last year, you discussed a lost corn license and a regulatory withdrawal at the Luling plant. I believe you quantified that as a 3% headwind. Could you give us a sense of what these headwinds could amount to if they materialized? Thank you.

Oliver Maier

executive
#37

Hey Peter, Oliver here. Honestly, that first question was really tough for me to follow. Could you possibly repeat it, maybe without a headset or something? Just checking.

Peter Verdult

analyst
#38

Yeah, Ollie, my apologies. Let me take another crack at that first question — it's a quick one. I was just thinking, since we're seeing consumer businesses in the market valued at 5x sales, how do Heiko or Werner think about making sure the buyer consumer business gets properly valued, given where the share price is right now and how well the consumer business is doing?

Werner Baumann

executive
#39

Peter, hello. Allow me to address the first question, if I may. Without question, the market is not assigning an appropriate value to our stock. Yes, you have heard this from us on multiple occasions, and it applies not only to the consumer business — it spans every segment. Given the robust results delivered in 2021 and the outlook for 2022, and beyond that the fact that we face a glyphosate situation for which we have made full provision under the scenario we foresee, we hope and expect our shares to recover their value, and that covers all of our businesses. We have likewise observed that, compared with the consolidation activity in the market, not every deal that was announced ultimately came to fruition. What we achieved in Consumer Health is evident on its own. Heiko will address it once more shortly. We have no problem standing firm, and we remain convinced that no one is better positioned than we are to own and run that business.

Heiko Schipper

executive
#40

Sure, I'll just add a few points to what Werner said. It demonstrates that Consumer Health is simply a highly appealing business, and that is the reason we are involved in it. Clearly, when you then combine that with performance that leads the industry, it becomes obvious that we have a very strong Consumer Health business, with very good brands, very good geographic performance, and also a very solid performance. Overall, I think it simply confirms that this is the right industry to be in, and that is the reason we are in it.

Oliver Maier

executive
#41

Peter, I believe that wraps up Consumer Health. Could you please repeat your second question? That one was difficult to follow as well.

Peter Verdult

analyst
#42

Apologies. I was told not to use a headset, but I had one on anyway. I hope my voice is coming through clearly at this point. The second question is for Rodrigo only, and it picks up where Vincent left off. You mentioned possible headwinds involving competitive supply and regulatory matters. Last year you faced comparable headwinds. I believe you put a number on them. I believe a core license was lost. There was a regulatory withdrawal in Europe, plus the plant closure in Louisiana. My recollection is that you quantified this at roughly 3%. I just want to hear from Rodrigo: if a few of those headwinds do materialize, what kind of quantification do we have in mind for those headwinds? Thank you.

Rodrigo Santos

executive
#43

Thanks. Thanks for that question. Let me be upfront about this. As we look at the market, and this echoes what I've heard across the whole industry, the main risk we see ahead is global supply. That's the one we're watching very carefully. There was one item we shared with you — glyphosate — which was a marginal factor for the full year, but it's something we're monitoring very closely. When it comes from a supplier to us, anticipating it is very difficult, but that's the one we're keeping a close eye on, right? That's probably the key one I'd say the entire industry will confront this year, even setting aside the geopolitical situation we touched on a little earlier today. On regulatory and competitive dynamics — we're going to have competitive dynamics, particularly in soybean rust, and some of that impact also relates to global regulatory matters we deal with; we may see something there. I'd say that if I were to highlight the one we're watching closely, it's the global supply point I just mentioned.

Peter Verdult

analyst
#44

Thanks.

Oliver Maier

executive
#45

Appreciate that, Peter.

Operator

operator
#46

Our following question comes from Michael Leuchten at UBS. You have the floor.

Michael Leuchten

analyst
#47

Thanks a lot for that. I have two questions, if I may. First, a clarification for Rodrigo. You've mentioned a few times now that you expect the majority of growth to come from pricing. How much of that price have you already realized, and how much remains for the year? And when you say you expect to gain market share, but you don't say you expect volume uptake, how does that work? Is it modest share gains you're anticipating, which is why volume uptake wouldn't be all that significant? Then a question for Werner. Looking at the annual report, the outstanding glyphosate cases stand at 138,000. When this process began, the figure was 125. That's clearly a very small uptick since then. I was just wondering if you could speak to the dynamic of new cases coming in — the cadence, so to speak. That would be helpful. Thank you.

Rodrigo Santos

executive
#48

Now, regarding the second half of your question on Crop Science, those points are quite clear-cut. Pricing is the primary growth engine for 2022, though we're also observing certain volume increases—specifically market-share gains in corn and some fungicide growth, especially across LatAm, with Fox Xpro and the new product we've launched. Pricing remains the key factor. Turning to the first half of your question: we're applying roughly a 6%-7% average price increase worldwide across our crop protection portfolio, leaving out glyphosate as well as our corn seeds and traits. If you look at the northern hemisphere—North America and Europe—that's the level of pricing we're using as we run and implement the campaigns. In tropical regions—Latin America more broadly and APAC—that will arrive during the latter portion of the year. Considering all the innovation we're delivering to the market, including all 500 seed deployments we're placing this year, I'm confident that this value-based pricing we're bringing will be something we can implement and carry out across the full year.

Werner Baumann

executive
#49

Okay, thank you, Rodrigo. Michael, regarding your question about the glyphosate cases: yes, as of February 1, we have roughly 138,000 cases. That count is rising extremely gradually. You've likely noticed that advertising activity has dropped quite a bit. Keeping the 138,000 figure in mind, we've settled 107,000, and that figure also takes in cases that aren't eligible since they fail to meet the criteria. You know? Around 30,000 remain, so that's not a significant change from the prior number. Just so everyone is clear on what's happening with those 30,000, we've chosen not to engage in any additional settlement talks for now while we await the Solicitor General's recommendation and see how the SCOTUS review develops further. Yeah, so no settlement activity is taking place at this moment.

Michael Leuchten

analyst
#50

Appreciate it.

Oliver Maier

executive
#51

Thanks, Michael.

Operator

operator
#52

Sachin Jain from Bank of America has the next question. Please go ahead.

Sachin Jain

analyst
#53

Sachin Jain from Bank of America here. I have two fairly simple questions from farmers, if I may. The first concerns Kerendia, which clearly signals a strong launch, Stefan. Would you expect it to rank among the top 15 products in 2022, or can you share any color on how sales might trend this year? Second, in your opening remarks you mentioned the Factor XI phase III decision coming by mid-year. I just have a couple of clarification questions on that, if I may. First, since you have multiple assets, is it possible to advance more than one? You cited potential differentiation in achieving efficacy without bleeding. Do you have any in-house data supporting that so far? You also mentioned the potential for this to be best in class. What makes you think that is the case? Thank you.

Stefan Oelrich

executive
#54

Thanks, Sachin. Those are two lengthy questions. On Kerendia, sadly my reply is on the brief side. It's somewhat soon to share more regarding this year. Our confidence in the uptake is strong. A great deal, clearly, depends on expanded access and on truly allowing everyone, beyond the programs we run to support patients, the chance to receive full reimbursement from payers. That work continues, and it will heavily influence how our sales curve looks this year. Beyond that, though, our optimism about Kerendia is high. Whether it enters the top 15 this year or the next is something we'll have to wait and see for now. Turning to Factor XI. I'm not sure I grasped the full thrust of what you asked, but let me attempt it if I understood correctly. The first part was about whether we plan to advance several Factor XI opportunities over the year, since three separate medicines of ours are in phase II at present. That's still under discussion, because what we're seeing makes us quite pleased, particularly with our oral program. Naturally, we would only move an injectable into phase III if our oral's profile cannot serve certain patients who would likewise gain from an injectable.

Stefan Oelrich

executive
#55

We feel really good about the results we're seeing. As you know, there's a limit to how much I can share ahead of presenting this at a scientific conference, which is planned for the upcoming American College of Cardiology. We've clearly reviewed some of the data our competitors have presented, and so our own data is on file, and that leaves us fairly optimistic about the various indications we plan to go after and about what we've observed up to now. I'd say we have a solid candidate, which reflects how experienced our company is at developing anticoagulants. After all, let's remember that we were the ones who designed the programs that turned Xarelto into what it is today.

Sachin Jain

analyst
#56

I appreciate that.

Stefan Oelrich

executive
#57

Appreciate it, Sachin.

Operator

operator
#58

The next question comes from James Quigley at Morgan Stanley. Your line is open.

James Quigley

analyst
#59

Hello, and thank you for taking my questions. I have one about the guidance and one about the pharma margin. On the guidance, when I work through it division by division, the group margin comes out looking somewhat conservative. Doing the math on the divisions points to roughly a 26.5% margin, compared with 26% for the group. Is a bit of conservatism built into that, or is there something I'm overlooking in that calculation? Then on the pharma margin, roughly 50 to 50 basis points, also rising in 2022 as you keep investing for growth. How far along are you with that investment? Should we expect the margin to begin edging up slowly from here, or is much of the cost already in the base, which would give potential from 2023 onwards for greater gross margin expansion? Thanks.

Wolfgang Nickl

executive
#60

Okay, James — it's Wolfgang here. I'll take the group question first, and after that Stefan will handle the pharma one. You've got a point. This comes down to rounding: we referred to 12% and EUR 12 billion of EBITDA and EUR 46 billion. Running the precise calculation gives you 26.1%. Our stated figure was around 26%, which means it might land slightly below or slightly above. Should you take the exact midpoint across all the components — and that seems to be the calculation you just performed — the result would come in higher than 26.1%. Whether that proved conservative we'll know once the year is over. As things stand, we see it at around 26%.

Stefan Oelrich

executive
#61

Thank you. Regarding the pharma margin, first off, I realize you likely already understand this, but our full-year accounting for launch investments involves many moving pieces, and there's also a reallocation of resources toward R&D. As a quick reminder, some of the acquisitions we completed have to be fully absorbed within our R&D line. Even with all of that, thanks to certain savings programs and our belt-tightening efforts, we are reaching the 32% guidance. That figure is also what we provided in our mid-term guidance, and we remain committed to it.

Operator

operator
#62

Mr. Quigley, are you done with your question?

James Quigley

analyst
#63

Yes. Thanks.

Operator

operator
#64

Our next question comes from Tony Jones at Redburn. Please go ahead.

Tony Jones

analyst
#65

Good afternoon, everyone, and thank you for taking my questions. I have two, and I believe both are for Wolfgang. Can you put a number on the EBITDA effect from supply chain disruption and cost inflation last year? Perhaps you could indicate whether you expect that to recur at a similar level in the current year. Then, on the higher Reconciliation charge, the EUR 500 million-EUR 600 million, is that a new recurring level, or is it simply a one-off higher charge in the current year? Thank you.

Wolfgang Nickl

executive
#66

Thank you very much. Regarding last year's EBITDA margin, you'll remember a number of factors were at play. The first was the STI catch-up, the second was currency, and the third was, in fact, the growth investments in R&D that Stefan just referred to. On top of that, there were inflationary pressures. We haven't itemized those and I doubt we will itemize them, but here's what I can say. I offered the small ocean freight illustration — active ingredients and energy would be further examples. Here's about as much as I can share. In a Crop Science business like Vividion with high COGS, we're looking at several hundred million EUR. That's fairly substantial. Naturally, Rodrigo, like Stefan and like Heiko, will make every effort to determine what they can build into their pricing and counterbalance through other efficiencies. That point is quite clear. As for the supply chain problems we faced last year, our growth figures will likely show you that those did not set us back especially dramatically. In the Crop Science situation, I'd say that's probably the clearest instance. We could have sold considerably more if we hadn't had the Ida effect at Luling. On reconciliation, we stood at EUR 488 million last year, and as a reminder to everyone, that is essentially the central cost for which we lack a suitable key to allocate across the divisions.

Wolfgang Nickl

executive
#67

There's some fluctuation given that STI and LTI normalizations are also included there. Our slight increase in 2022 comes from two primary causes. First, we're beginning the upgrade of our ERP systems. That's fairly broad work, so it isn't tied specifically to Vividion, which is why we've placed it in reconciliation. Second, as you might expect, a company our size pays a considerable amount in insurance premiums, and we've watched that market rise in price quite substantially, just as every other company has. That's the second item. Again, at this point there are several moving pieces involved. My hope is that we'll hold it below that level going forward. At present we're at 22, and we'll give you an update on the timing afterward in due course. I hope that's helpful.

Tony Jones

analyst
#68

Thanks. That's really useful. Yeah, I appreciate it.

Stefan Oelrich

executive
#69

Thanks, Tony Jones.

Operator

operator
#70

Next up, we have a question from Richard Vosser at JPMorgan. The line is yours.

Richard Vosser

analyst
#71

Hello, and thank you for the opportunity to ask. I have a question about those cost pressures from inflation. Clearly, energy prices are rising, and there is geopolitical uncertainty. So could you discuss what access you have to long-term contracts, what their duration is, and how you have approached this, as well as the adjustments to those in your guidance? Second, to return to those glyphosate figures regarding the rise in cases: obviously, a very low increase in cases — is that consistent with the expectations you hold for provisioning, and do you keep seeing case volume decline? So some thoughts on that provisioning and give us some sense there. Thank you very much.

Werner Baumann

executive
#72

On your inflation question — honestly, that's quite hard to answer in broad terms. We do have quite a few long-term contracts in place. In fact, that's proving really useful given the enormous inflation we're seeing and the cost pressure on energy supplies. The fact that we now hold long-term contracts covering roughly 25% of our energy bills in renewables is a substantial help in curbing those cost increases. Second, speaking more broadly about our energy footprint, and the significant cost rise that many others are talking about — on our side, we're no longer such an energy-intensive business. All told, our energy costs, including steam and a few other items, come to about EUR half a billion. Against a top line of EUR 44 billion to EUR 46 billion, we will of course see increases, but we believe we can absorb them. As Rodrigo and Heiko mentioned, we're also well positioned on pricing thanks to the inflationary trends we're seeing everywhere, and we'll pass those through very aggressively. Then there are other areas where, let's say, the task at hand looks different.

Werner Baumann

executive
#73

Even though we’re facing higher costs, securing supply is what matters most. Rodrigo mentioned this earlier. We’re seeing supply chains under extreme strain, with a very, very high risk of default, and that’s what we’re managing so we can keep producing and supplying — that’s the current focus, and it’s what our procurement organization is working on. The second point on the claims increases: we’ve just closed the books, the books have been audited, and the provisions have, you know, passed the test of being appropriate. There’s no significant movement in either direction that would shape our view on whether those provisions are appropriate or not for this argument about their status. Yeah. We’re very prepared for that set of factors, and also for the currencies that have entered our calculus, so no change.

Richard Vosser

analyst
#74

Appreciate it, Werner.

Werner Baumann

executive
#75

Thanks, Richard.

Operator

operator
#76

Sebastian Bray from Berenberg is up next on the line. You have the floor.

Sebastian Bray

analyst
#77

Hello, and thanks for taking my question. I have two, please. The first concerns what is driving the guidance in Crop Science, and specifically what has happened since the Monsanto acquisition. Am I correct that negative FX effects have taken out roughly EUR 1 billion of EBITDA in euro terms from Crop Science since late 2018? On the earlier points about competition in soybean, if we went back to an FX environment like 2018, does all of that come back, or has some of it been given up to drive market share gains? My second question is about working capital. Could you remind us what you typically carry as a percentage of sales growth for Crop Science and Pharma? Is it about 20%-25%? Thank you.

Werner Baumann

executive
#78

Okay, Sebastian — Rodrigo is going to handle the first part, and then Wolfgang will cover your second question about working capital.

Rodrigo Santos

executive
#79

Let me start with the first item. I believe we're leveraging our entire portfolio in the marketplace. We just recently announced our pipeline review, where we moved forward roughly 500 seed deployments, and at the same time, over 300 product registrations in crop protection. That's why I brought up that in crop protection, we have a price increase comparable to what we see in corn seeds and traits, roughly 6%-7% on average globally. Certain locations see double-digit pricing, while other regions differ. We're fully leveraging our whole portfolio to fuel the growth we're experiencing this year. I think that's one element. Now on soybeans. Let me break the soybean conversation into parts. First, South America and Brazil. We just introduced Intacta 2 Xtend on 800,000 acres. We're seeing that expand to 6 million acres. We have a 5% price increase, so again we're seeing strong dynamics in Brazil. The U.S. is a more competitive market, and we'll be competing there as we did last year. I think the launch of XtendFlex on 16 million acres was very important for us.

Rodrigo Santos

executive
#80

We hold the top spot in weed control across North America, and we're going to keep defending that through this year. When I look at the growth we have lined up for 2022, I believe we're leveraging our entire portfolio. Where opportunities exist, we're making the most of them, and we're reducing the risks we mentioned earlier. That's a quick overview of Crop Science from my side. I hope that addressed your question.

Wolfgang Nickl

executive
#81

I also invest, and I'll get into the working capital topic, and I'll approach it more from a corporate angle. To start with, we're fairly happy with what all the teams achieved last year. Our free cash flow came in much stronger than our forecast. Across the whole company, the ratio of working capital to sales landed somewhere between 37% and, say, 34%. I think it matters, when you examine this for crop specifically, that prepays are also factored in, since the usual receivables, inventory, and payables won't get you there, because we always carry very sizable prepays in that business. Once that's factored in, it's roughly in line with the corporate average. I hope that answers your question, Sebastian.

Sebastian Bray

analyst
#82

Yes, absolutely. Thanks for taking my question.

Wolfgang Nickl

executive
#83

Glad to have you with us.

Rodrigo Santos

executive
#84

Thanks, Sebastian.

Operator

operator
#85

Our following question comes from Jo Walton at Credit Suisse. Please proceed.

Jo Walton

analyst
#86

Thank you. There are two questions I have. First, I’d like to hear more detail about how your operations in Russia and Ukraine are being affected. Assuming conditions remain unchanged — and it is clearly very hard to move goods into and out of Ukraine and Russia given sanctions — could you give us a sense of the potential effect on your business? On the pharma side, Eylea is clearly performing very strongly, and you indicate that the launch of the prefilled syringes accounts for part of that. We recently received the two-year data for faricimab. Could you tell us how you see Eylea — especially perhaps the 8-milligram Eylea — competing against that two-year faricimab data, and as a result, how long Eylea can be expected to keep growing, disregarding anything related to patent expiries. Many thanks.

Operator

operator
#87

Hi, Mr. Maier. Are you able to hear us?

Werner Baumann

executive
#88

Serving what you might call the most basic requirements every one of us shares — namely, getting food and getting your health and health supplies. As things stand right now, sanctions impose no restrictions in this area. Naturally, politics will dictate terms for us, and we'll comply with those and follow them. At this moment, I believe every one of the sanctions is built to target those holding power and to shield those hurting most from the situation, and that really means the civilian population. Our products are exactly what we must keep supplying to these people, since many of them are, you know, reliant on our medicines, and they have to be able to get them, yeah. We will go out of our way to make sure they receive them. Second, the broader picture in Ukraine and in Russia obviously keeps shifting hour by hour. We have robust crisis management resources and teams reporting to the board on this subject where supply is concerned, and where it comes to making certain our logistics are in place — transport is among the bigger challenges at the moment.

Werner Baumann

executive
#89

So first of all, the most important thing is that we look after our own employees in these countries. Right now, people have some extremely fundamental needs. One of them is access to safe housing and shelter, which we're arranging and supplying, along with a great many private efforts, for our people on the ground. Second, as you've seen in the news pictures, people are unable to get their hands on cash. We're giving our people in Ukraine advance cash payments so they can cover, let's say, their most pressing local needs. Yeah. Beyond that, you know, we really have to take it hour by hour.

Stefan Oelrich

executive
#90

Hey, Joe. It's Stefan. Appreciate your question about Eylea. Good to see you're tracking this so closely — and particularly the really strong growth momentum we've got going. Yeah, we're also keeping an eye on what's coming out on the clinical data side from faricimab. Honestly, it looks solid, and they're closing the gap on us. I mean, at the doses we already have, our treatment offers a four-month dosing interval with treat and extend. They're now catching up to that with what they've got. I'd say we've stayed a step ahead right up until now. On growth, that's certainly something we'll need to speak to — including the peak sales we can reach with Eylea going forward — because we're impressed by how solid Eylea is. My sense is we can look for continued growth over the coming years, held back only by loss of exclusivity, which will come around 2025.

Operator

operator
#91

The following question comes from Falko Friedrichs. You have the floor.

Falko Friedrichs

analyst
#92

Hello. This is Falko Friedrichs calling from Deutsche Bank. Thank you for taking my questions. I have two as well, please. The first returns to your Crop Science guidance. Taking the 7% organic growth you're pointing to, you've said several times during this call that price should make up most of it. Would it be fair for us to assume the split is roughly 5% price and 2% volume in 2022? And if that's right, I still don't entirely see why volume growth shouldn't be larger this year. That's my first question. Then the second concerns pharma. You said that Xarelto's volume growth should largely offset the VBP impact. So would it be a fair assumption to expect low single-digit growth for the drug in 2022? Thank you.

Rodrigo Santos

executive
#93

Let me tackle that question first. Yeah, I'd say it's fair to call that a reinforcement of the point I raised. Right. Pricing is what mainly drives our growth, as we see it. There's also some volume gain in corn that I mentioned, particularly from picking up market share, plus the expansion of fungicide. At the same time, the plan does include some negatives — the higher costs and a few other pieces of that equation. On the whole, I'd say pricing accounts for by far the majority of the growth we have for 2023. Half of it comes from the herbicide line, and half comes from mainly all the remaining crop protection products and the corn. That's right. That's right.

Stefan Oelrich

executive
#94

Yes. Thanks for asking about Xarelto, Falko. I believe it's worth giving you some additional detail here. In 2021, we were indeed able to offset the price reductions through higher volumes. For 2022, since we'll have a full year of VBP impact in China, that will be considerably more difficult. Given how important China is, what we anticipate is that this year we could see a slight decline even in Xarelto during 2022. We're clearly monitoring this closely, because Europe remains strong. We are now seeing the first impact, particularly via China. 2022 is a challenging year for us.

Falko Friedrichs

analyst
#95

Alright, thanks. Just one quick follow-up for Rodrigo, if I can. When you put together that guidance, is the assumption baked in that in 2022 you gain share in corn while giving up share in soy?

Rodrigo Santos

executive
#96

On corn, we're picking up share. With soybeans, we aren't building that assumption in. I'd say we're not looking at any major expansion on the soybean side — that's a fair way to put it. When it comes to the volumes we've planned, particularly in North America — which is different from what I said regarding South America, right? Soybean always comes up. I want to break that equation apart. In South America, the Intacta 2 Xtend platform is expanding substantially. Momentum there is strong, and it's going to keep being strong. In the U.S. market, the environment is more competitive, and in our plans we aren't planning a significant expansion.

Falko Friedrichs

analyst
#97

Alright, thanks.

Werner Baumann

executive
#98

Thanks, Rodrigo.

Operator

operator
#99

Ladies and gentlemen, we ask for your understanding that time constraints require us to end the call at this point. My apologies, Mr. Maier. Kindly go ahead with whatever other points you would like to bring up.

Oliver Maier

executive
#100

Thanks a lot, Nairobi — I really appreciate it. And thank you, everyone, for spending part of your day with us and for your focus. It means a great deal. That wraps up today’s call. Take care, and we’ll speak again before long. Many thanks.

Operator

operator
#101

That wraps up Bayer AG's conference call for investors and analysts covering the fourth quarter and the full year 2021, everyone. We appreciate your joining us. You're welcome to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.